关于中国精神分裂症患者一线治疗中布隆色林与齐拉西酮的成本效益分析的更正

{"title":"关于中国精神分裂症患者一线治疗中布隆色林与齐拉西酮的成本效益分析的更正","authors":"Lianhuan Xin","doi":"10.54844/hd.2023.0498","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"222 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Erratum on Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China\",\"authors\":\"Lianhuan Xin\",\"doi\":\"10.54844/hd.2023.0498\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":430023,\"journal\":{\"name\":\"Health Decision\",\"volume\":\"222 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Decision\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54844/hd.2023.0498\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Decision","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54844/hd.2023.0498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}